厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效
The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer
厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效 |
|
评价者:冯卫能 |
The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer |
| |